Search
for
Sort by
Research 391–420 of 1000+
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- In vitro and In vivo Effects of 17β-N-(4-phenylcarbamoyl) androst-4-en-3- one Derivatives as 5a-reductase Inhibitors on Androgen-dependent Glands
- P122 : Flavonoid silibinin induces hair growth in 3-dimensional cultured human dermal papilla cells
- Crystal Structure and Synthesis of 17α-Acetoxy-4-bromopregn-4-ene-3,20-dione
- Subject Index Vol. 3, 2002
- Expression of Signal Transducer and Activator of Transcription-3 in Androgenetic Alopecia: A case control study
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol
- Alopecia Areata Increases the Risk of Stroke: a 3-year Follow-Up Study
- The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia
- Nongenomic effects of 1α,25-dihydroxyvitamin D 3 on cartilage formation deduced from comparisons between Cyp27b1 and Vdr knockout mice
- Erratum to: Evaluation of the Effect of NT-3 and Biodegradable Poly-L-lactic Acid Nanofiber Scaffolds on Differentiation of Rat Hair Follicle Stem Cells into Neural Cells In Vitro
- Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series
- Relation between treatment efficacy and cumulative dose of 3% topical minoxidil in male pattern baldness
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Crystal Structure and Synthesis of 17α-Hexanoyloxy-16β-methylpregna-4,6-diene-3,20-dione
- Katsuwonus pelamis heart hydrolysates promote hair growth in 3-dimensional human hair follicle organoids and in mice
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- An Adult With Hair Loss! a Rare Case of Non-Classical 3β Hydroxysteroid Dehydrogenase (3β HSD) Deficiency
- Prospective non-randomized controlled Clinical trial on the efficacy of finasteride and 3% minoxidil Co.for the treatment of androgenetic alopecia in Chinese men
- Case 2-2022: An Adolescent Male in Cardiac Arrest 3 Days After Liver Transplantation for End-Stage Liver Disease
- Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
- Electronic Brachytherapy for the Treatment of Nonmelanoma Skin Cancer: Results at 3 Years
- Clinical and epidemiological characteristics and condition of the hormonal status in women with androgenetic alopecia (1139.3)
- Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
- The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
- Generation of human-induced pluripotent stem cell-derived adherent 3-dimensional skin hair-follicle organoids
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment